SBP GROUP (01177.HK): Enters Exclusive Licensing Agreement with Cipla for TQB2102, with Deal Value Up to USD 123 Million

NewTimeSpace News: On August 31, 2026, Sino Biopharmaceutical Limited (stock code: 01177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) has entered into an exclusive license and supply agreement with Cipla Limited (Cipla) for TQB2102 (rolditamig deuderuxtecan), the Group's self-developed HER2 bispecific antibody-drug conjugate (ADC).

According to the announcement, this is the second regional licensing collaboration for TQB2102, and the two collaborations have together brought the Group approximately USD 30 million in upfront and milestone payments to date. Under the agreement, the Group will grant Cipla an exclusive license to develop and commercialize TQB2102 in India, South Africa and five other emerging markets (the licensed territories). Cipla will be responsible for local clinical development, regulatory filings and commercialization in the licensed territories, while CTTQ will continue to be responsible for the manufacture and supply of TQB2102. The Group is entitled to upfront payments and potential development, regulatory and sales milestone payments of up to USD 123 million, plus double-digit royalties based on TQB2102's annual net sales.

TQB2102 is a next-generation HER2 biparatopic bispecific antibody-drug conjugate developed by the Group, targeting both the ECD II and ECD IV domains of HER2. Phase Ib results presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting showed an overall response rate (ORR) of 53.4% (39/73) in advanced HER2-low breast cancer, with an interstitial lung disease (ILD) incidence of 0.55%. The drug has received three breakthrough therapy designations from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration, and multiple Phase III studies are ongoing; the Group will present Phase III data in HER2-low breast cancer as a late-breaking abstract (LBA) at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting.

Founded in 1935, Cipla is a global pharmaceutical company with 48 manufacturing sites, operating in more than 70 markets worldwide and ranking as India's third-largest pharmaceutical company. The Group stated that the collaboration leverages Cipla's local capabilities and market access advantages in the licensed territories to advance the Group's internationalization strategy, and is expected to improve the global accessibility of TQB2102.

The source of this information is the HKEX announcement.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.